Medicare AdvantagePrior AuthMedium impact
Lifyorli (relacorilant) (New)
Humana·Oncology, OB-GYN·Medicare Advantage
Effective date
May 27, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage has established a new prior authorization policy for Lifyorli (relacorilant), a cancer medication used for platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. The drug requires prior authorization and must meet specific criteria including combination use with nab-paclitaxel and prior treatment history including bevacizumab.
Action Required
By May 27, 2026: Billing and clinical teams must implement prior authorization requirements for Lifyorli (relacorilant) prescriptions for Humana Medicare Advantage patients. Verify patients meet all four criteria: diagnosis of epithelial ovarian/fallopian tube/primary peritoneal cancer, platinum-resistant disease, combination use with nab-paclitaxel, and 1-3 prior systemic treatments including bevacizumab. Update EMR templates to capture required documentation. Claims will be denied without proper prior authorization.